Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 11, 2013 | VP, Program Management | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| Apr 15, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | $12.50 | 55,000 | |
| Apr 15, 2015 | VP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 5,000 | $12.50 | 50,000 | |
| Apr 15, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | -- | 30,000 | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 6,043 | $11.68 | 57,751 | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 6,043 | $11.68 | 51,708 | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 1,708 | $12.11 | 50,000 | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 543 | -- | -- | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,000 | -- | -- | |
| Mar 20, 2015 | VP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 3,500 | -- | 26,500 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.